The Food and Drug Administration (FDA) is evaluating the risk of gadolinium based contrast agents (GBCAs) leaving brain deposits with repeated use. GBCAs are used to help detect abnormalities in organs, tissues and blood vessels in Magnetic Resonance Imaging (MRI) scans. Recent studies and publications have reported deposits remain in the brain of patients that have received four or more MRI scans using GBCAs years after receiving the last dose…

On July 8, 2015 the Centers for Medicare & Medicaid Services (CMS) proposed a rule that updates payment policies, payment rates, and quality provisions for services under the Medicare Physician Fee Schedule (PFS) on or after January 1, 2016. The rule also finalizes changes to the quality reporting initiatives associated with PFS payments, including the Physician Quality Reporting System (PQRS)…